Abstract
Seventy patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP). The complete remission rate of 75-7% compares well with that produced by other combinations. The combination is non-toxic, easily administered and can be given safely to outpatients. Its main advantage is that it is far less upsetting to patients than combinations containing nitrogen mustard.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
McElwain, T., Toy, J., Smith, E. et al. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer 36, 276–280 (1977). https://doi.org/10.1038/bjc.1977.187
Issue Date:
DOI: https://doi.org/10.1038/bjc.1977.187
- Springer Nature Limited
This article is cited by
-
Current Treatment Options for Older Patients with Hodgkin Lymphoma
Current Treatment Options in Oncology (2020)
-
Treatment of Hodgkin lymphoma: the past, present, and future
Nature Clinical Practice Oncology (2008)
-
Childhood lymphoma
The Indian Journal of Pediatrics (1998)
-
Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and ?,?-difluorochlorambucil (CB 7103) in mice
Cancer Chemotherapy and Pharmacology (1986)
-
Prognostic factors in COPP-treated patients with Hodgkin's disease
Blut (1982)